JP6005736B2 - Ｉｌ−１２を用いる皮膚損傷の軽減 - Google Patents

Ｉｌ−１２を用いる皮膚損傷の軽減 Download PDF

Info

Publication number
JP6005736B2
JP6005736B2 JP2014515934A JP2014515934A JP6005736B2 JP 6005736 B2 JP6005736 B2 JP 6005736B2 JP 2014515934 A JP2014515934 A JP 2014515934A JP 2014515934 A JP2014515934 A JP 2014515934A JP 6005736 B2 JP6005736 B2 JP 6005736B2
Authority
JP
Japan
Prior art keywords
wound
pharmaceutical composition
administration
skin
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014515934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014517038A5 (enExample
JP2014517038A (ja
Inventor
バジーレ，レナ，エー．
エルフソン，ドルフ
ギャラハー，ティモシー，ケー．
Original Assignee
ニューメディシンズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューメディシンズ，インコーポレーテッド filed Critical ニューメディシンズ，インコーポレーテッド
Publication of JP2014517038A publication Critical patent/JP2014517038A/ja
Publication of JP2014517038A5 publication Critical patent/JP2014517038A5/ja
Application granted granted Critical
Publication of JP6005736B2 publication Critical patent/JP6005736B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2014515934A 2011-06-13 2012-06-13 Ｉｌ−１２を用いる皮膚損傷の軽減 Active JP6005736B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161496472P 2011-06-13 2011-06-13
US61/496,472 2011-06-13
US201161528053P 2011-08-26 2011-08-26
US61/528,053 2011-08-26
PCT/US2012/042165 WO2012174056A1 (en) 2011-06-13 2012-06-13 Mitigation of cutaneous injury with il-12

Publications (3)

Publication Number Publication Date
JP2014517038A JP2014517038A (ja) 2014-07-17
JP2014517038A5 JP2014517038A5 (enExample) 2015-07-30
JP6005736B2 true JP6005736B2 (ja) 2016-10-12

Family

ID=47357436

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014515934A Active JP6005736B2 (ja) 2011-06-13 2012-06-13 Ｉｌ−１２を用いる皮膚損傷の軽減

Country Status (5)

Country Link
US (1) US9925246B2 (enExample)
EP (1) EP2718456B1 (enExample)
JP (1) JP6005736B2 (enExample)
CA (1) CA2839261A1 (enExample)
WO (1) WO2012174056A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018017571A1 (en) * 2016-07-18 2018-01-25 Neumedicines, Inc. Uses of il-12 as a replacement immunotherapeutic
JP7045671B2 (ja) * 2018-11-12 2022-04-01 有限会社バイオ研 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材
JP7448137B2 (ja) * 2020-03-10 2024-03-12 日本ゼトック株式会社 アクチン重合促進剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US5573764A (en) 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
ATE216590T1 (de) 1995-02-06 2002-05-15 Genetics Inst Arzneimittelformulierungen für il-12
US5853714A (en) 1995-03-27 1998-12-29 Genetics Institute, Inc. Method for purification of IL-12
AU761520B2 (en) * 1998-09-15 2003-06-05 Genetics Institute, Llc Treatment of Kaposi's Sarcoma with IL-12
US7052685B1 (en) 1998-10-15 2006-05-30 Trustees Of The University Of Pennsylvania Methods for treatment of cutaneous T-cell lymphoma
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2004058178A2 (en) * 2002-12-23 2004-07-15 Schering Corporation Uses of mammalian cytokine; related reagents
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
US7939058B2 (en) * 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
EP1641431B1 (en) * 2003-07-03 2018-01-10 University Of Southern California Uses of il-12 for reducing the toxicity of chemo- and/or radio-therapy
AU2005277404A1 (en) 2004-08-20 2006-03-02 Smithkline Beecham Corporation Methods of healing wounds by administering human IL-18
US8165819B2 (en) * 2006-10-10 2012-04-24 The University of Pittsburgh—Of the Commonwealth System of Higher Education Modeling wound healing
WO2010135655A2 (en) 2009-05-21 2010-11-25 Stratatech Corporation Human skin substitutes expressing il-12

Also Published As

Publication number Publication date
US20140205561A1 (en) 2014-07-24
US9925246B2 (en) 2018-03-27
CA2839261A1 (en) 2012-12-20
JP2014517038A (ja) 2014-07-17
WO2012174056A1 (en) 2012-12-20
EP2718456A1 (en) 2014-04-16
EP2718456B1 (en) 2019-04-24
EP2718456A4 (en) 2014-11-19

Similar Documents

Publication Publication Date Title
US6387364B1 (en) Methods of healing wounds and fibrotic disorders using IL-10
EP2222330B1 (de) Behandlung inflammatorischer krankheiten mit ace2
US9314505B2 (en) Combination treatments and compositions for wound healing comprising viral VEGF
US11826486B2 (en) Methods for treating wounds
JP2008523101A (ja) 爪ユニットの状態を治療するための組成物および方法
JP6005736B2 (ja) Ｉｌ−１２を用いる皮膚損傷の軽減
JP2019524753A (ja) 置換免疫療法薬としてのｉｌ−１２の使用
EP2572724B1 (de) Behandlung von Fibrosen und Lebererkrankungen
Reksodiputro et al. Platelet-rich fibrin enhances wound epithelialization in the skin graft donor site
Furudoi et al. Balance of tumor necrosis factor alpha and interleukin-10 in a buccal infection in a streptozotocin-induced diabetic rat model
US20240016893A1 (en) Compositions and methods for treating wounds
CA2669109A1 (en) Il-17b for use in wound healing
CN116920077A (zh) 血小板衍生生长因子在制备褥疮治疗药物中的应用
US20080159979A1 (en) Treatment of wounds using il-17b
Abdel Gawad et al. Effect of the use of the human amniotic membrane in healing of surgically induced skin defects in rabbits (histopathological study)
Santhan A Comparative Study between Efficacy Of Topical Sucralfate And 5% Povidone Iodine In Chronic Lower Limb Ulcers
US20070025963A1 (en) Methods for reduction of scar tissue formation
JP2022525935A (ja) 糖尿病性足部潰瘍の治療における上皮細胞増殖因子の使用
Riyaz A Comparative Study of the Efficacy of Topical Hydrogel Dressings and Conventional Dressings in Chronic Wounds
Shakir et al. Biopatterned Recombinant Human Bone Morphogenetic Protein 2 Does Not Induce Pansynostosis or Growth Restriction in the Immature Craniofacial Skeleton
HK1240851B (en) Compositions for treating wounds
DE102007040932A1 (de) Flüssigformulierung von G-CSF

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150611

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160705

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160809

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160907

R150 Certificate of patent or registration of utility model

Ref document number: 6005736

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250